Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUCCESSOR-2: Mezigdomide + Carfilzomib + Dexamethasone vs Carfilzomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma
2022-500861-29-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Jan 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival (PFS). Planned start Jan 2023; status: authorised.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-500861-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500861-29-00.